To date, relatively nonspecific measures of neuronal injury, such as plasma levels of neurofilament light chain (NfL)9, 10 or glial function, such as glial fibrillary acidic protein (GFAP),11 and other proteomic biomarkers have emerged as potential candidate pharmacodynamic biomarkers for FTD clinical trials, whereas lipidomic biomarkers have been less investigated. This evidence concerns the gene GFAP and frontotemporal dementia.